

NOVARTIS AG  
Form 6-K  
January 25, 2017  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Report on Form 6-K dated January 25, 2017  
(Commission File No. 1-15024)**

Novartis AG  
(Name of Registrant)

**Lichtstrasse 35  
4056 Basel  
Switzerland**  
(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

**Form 20-F**  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

---

**Exhibits:**

99.1 Excerpts from Novartis Annual Report 2016

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: January 25, 2017

**Novartis AG**

By: /s/ HARRY KIRSCH

Name: Harry Kirsch

Title: Chief Financial Officer, Novartis Group

By: /s/ FELIX R. EHRAT

Name: Felix R. Ehrat

Title: General Counsel, Novartis Group

---